With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.234108-58-8,tert-Butyl 4-(2-aminoethyl)-3-oxopiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.
B. 4-(tert-Butyloxycarbonyl)-1-[2-(2,3 5,6-tetrachloropyridin-4-ylamino)-ethyl]-piperazin-2-one. 4-(tert-Butyloxycarbonyl)-1-(2-aminoethyl)-piperazin-2-one (4.0 g, 16 mmol) is dissolved in methylene chloride (150 ML) and treated with 4-nitro-2,3,5,6-tetrachloro-pyridine (4.8 g, 18 mmol) and N-methylmorpholine (4.0 ML, 36 mmol).The reaction mixture is stirred for 5 h, concentrated and the residue is purified by chromatography (50% ethyl acetate/hexane) to give the title compound (4.8 g, 10.5 mmol).Fab MS m/z: 457, 469, 461, [M+1]+; 1H NMR (CDCl3, 300 MHz) delta6.00 (t, 1H), 4.10 (s, 2H), 3.97 (m, 2H), 3.66 (m, 2H), 3.38 (m, 2H)., 234108-58-8
The synthetic route of 234108-58-8 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; AVENTIS PHARMACEUTICALS INC.; US2004/102450; (2004); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics